Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Dextromethorphan abuse

Tony Antoniou and David N. Juurlink
CMAJ November 04, 2014 186 (16) E631; DOI: https://doi.org/10.1503/cmaj.131676
Tony Antoniou
Department of Family and Community Medicine (Antoniou), St. Michael’s Hospital; Department of Family and Community Medicine (Antoniou), University of Toronto; Institute for Clinical Evaluative Sciences (Juurlink); Department of Medicine (Juurlink), Sunnybrook Health Sciences Centre, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tantoniou@smh.ca
David N. Juurlink
Department of Family and Community Medicine (Antoniou), St. Michael’s Hospital; Department of Family and Community Medicine (Antoniou), University of Toronto; Institute for Clinical Evaluative Sciences (Juurlink); Department of Medicine (Juurlink), Sunnybrook Health Sciences Centre, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Dextromethorphan is more than an innocuous antitussive

At large doses used recreationally (300 to > 1500 mg), dextromethorphan and its metabolite dextrophan block N-methyl-d-aspartate receptors, producing dissociative effects similar to those of phencyclidine and ketamine.1 Neurobehavioural effects can begin within one hour after ingestion, are dose-related and are described by users as occurring in “plateaus” (Box 1).2,3 Adrenergic effects (e.g., hypertension, diaphoresis) can result from dose-related inhibition of catecholamine reuptake, and serotonergic effects can result from agonist effects at serotonin receptors.4 Serotonin syndrome can also arise from interactions with serotonergic drugs.2,3

Box 1:

“Plateaus” of dextromethorphan toxicity*,2,3

Plateau 1 (1.5–2.5 mg/kg)

  • Total intake 100–200 mg (4–6 capsules or 35–60 mL of syrup)

  • Restlessness, euphoria

Plateau 2 (2.5–7.5 mg/kg)

  • Total dose 200–500 mg (7–18 capsules or 60–185 mL of syrup)

  • Exaggerated auditory and visual sensations, closed-eye hallucinations, imbalance

Plateau 3 (7.5–15 mg/kg)

  • Total dose 500–1000 mg (18–33 capsules or 185–375 mL of syrup)

  • Visual and auditory disturbances, altered consciousness, delayed reaction times, mania, panic, partial dissociation

Plateau 4 (> 15 mg/kg)

  • Total dose > 1000 mg (> 33 capsules or > 375 mL of syrup)

  • Hallucinations, delusions, ataxia, complete dissociation

  • ↵* Assuming a 75-kg person, 30-mg capsules and 3 mg per millilitre of syrup.

Use is increasing among adolescents

According to the Ontario Student Drug Use and Health Survey, 9.7% of students in grades 7 to 12 reported using dextromethorphan recreationally in 2013, compared with 6.9% in 2011.5 Most dextromethorphan-related calls to poison control centres involve adolescent males and solid dose formulations of the drug.6

Clinical effects may be influenced by combined-formulation drugs

Some effects attributed to dextromethorphan may reflect ingestion of combination drugs, particularly decongestants, acetaminophen and anticholinergic antihistamines.2,4 Because dextromethorphan is not detected by basic drug screens, toxicity secondary to its use should be considered when evaluating patients with a dissociative toxidrome.2,4

Treatment is supportive

No specific antidote exists for dextromethorphan toxicity.3,5 Guidelines suggest benzodiazepines for seizures and aggressive cooling measures for hyperthermia. Naloxone can be considered for use in patients in a coma or with respiratory depression, although clinical response is varied.2,4 Acetaminophen levels should be obtained when concomitant ingestion is suspected, and additional measures for the management of associated complications (e.g., delayed hepatic injury related to acetaminophen overdose) implemented as appropriate.2,4

Withdrawal can occur

Anecdotal reports from long-term users (i.e., months to years) have described intense cravings, flashbacks and hallucinations within three days after stopping dextromethorphan.2,3 Physical symptoms of withdrawal include diarrhea, vomiting and rigors. Symptoms typically resolve within two days without specific treatment.1

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 186 (16)
CMAJ
Vol. 186, Issue 16
4 Nov 2014
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dextromethorphan abuse
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Dextromethorphan abuse
Tony Antoniou, David N. Juurlink
CMAJ Nov 2014, 186 (16) E631; DOI: 10.1503/cmaj.131676

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Dextromethorphan abuse
Tony Antoniou, David N. Juurlink
CMAJ Nov 2014, 186 (16) E631; DOI: 10.1503/cmaj.131676
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Dextromethorphan is more than an innocuous antitussive
    • Use is increasing among adolescents
    • Clinical effects may be influenced by combined-formulation drugs
    • Treatment is supportive
    • Withdrawal can occur
    • Footnotes
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • A cross-sectional examination of medicinal substance abuse and use of nonmedicinal substances among Canadian youth: findings from the 2012-2013 Youth Smoking Survey
  • Google Scholar

More in this TOC Section

  • Bedbugs
  • Achalasia with megaesophagus
  • Epinephrine in anaphylaxis
Show more Practice

Similar Articles

Collections

  • Article Types
    • Five Things to Know About
  • Topics
    • Addiction medicine
    • Drugs: psychotherapeutic
    • Patient safety & quality improvement
    • Men's health
    • HIV & AIDS
    • Drugs: hormones & metabolic agents
    • Drugs: polypharmacy
    • Drugs: gastrointestinal system
    • Drugs: central nervous system (not psychiatric)
    • Drugs: cardiovascular system
    • Drugs: adverse reactions
    • Anesthesia & analgesia
    • Pharmacology & toxicology

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire